ContraFect to Present at Biotech Showcase 2019
20 déc. 2018 17h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Dec. 20, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Present at Piper Jaffray Health Care Conference
19 nov. 2018 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Nov. 19, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect Appoints Michael Messinger as Chief Financial Officer
12 nov. 2018 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Nov. 12, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect Announces Third Quarter 2018 Financial Results
08 nov. 2018 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Nov. 08, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Participate in World Antimicrobial Resistance Congress 2018
22 oct. 2018 17h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Oct. 22, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Present at Two Upcoming Investor Conferences
20 sept. 2018 17h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Sept. 20, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect Completes Enrollment in Phase 2 Clinical Trial Evaluating CF-301 (exebacase) in Patients with Staphylococcus Aureus Bacteremia
06 sept. 2018 08h30 HE
|
ContraFect Corporation
YONKERS, N.Y., Sept. 06, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Present at Two Upcoming Investor Conferences
29 août 2018 17h30 HE
|
ContraFect Corporation
YONKERS, N.Y., Aug. 29, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Present at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
22 août 2018 17h00 HE
|
ContraFect Corporation
YONKERS, New York, Aug. 22, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect Announces Second Quarter 2018 Financial Results
09 août 2018 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Aug. 09, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...